RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$27.91

18 May
2022

-0.010

OPEN

$28.11

-0.04%

HIGH

$28.17

1,347,282

LOW

$27.83

TARGET
$35.438 27.0% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY22
Forecast
FY23
Forecast
EPS (cps) 78.9 xxx
DPS (cps) 23.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 35.2 xxx
Dividend Yield 0.8% xxx
Div Pay Ratio(%) 29.1% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.36%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.80

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 11/05 - ex-div 4.14c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx43.8
DPS All xxxxxxxxxxxxxxx14.6
Sales/Revenue xxxxxxxxxxxxxxx4,285.6 M
Book Value Per Share xxxxxxxxxxxxxxx263.9
Net Operating Cash Flow xxxxxxxxxxxxxxx987.6 M
Net Profit Margin xxxxxxxxxxxxxxx14.84 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx17.03 %
Return on Invested Capital xxxxxxxxxxxxxxx12.33 %
Return on Assets xxxxxxxxxxxxxxx9.82 %
Return on Equity xxxxxxxxxxxxxxx17.03 %
Return on Total Capital xxxxxxxxxxxxxxx23.49 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx546.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

02/05/2022

3

Equal-weight

$26.90

-3.62%

ResMed competitor Philips has increased the number of its devices requiring recall, leading Morgan Stanley to now assume completion of remediation will occur three months later than previously thought (now March Q 2023).

This would be good news for ResMed but for the supply chain issues/costs impairing its ability to take advantage. The company has lowered its expected revenue benefit target by -US$100m to US$200-250m in FY22 with gross margins under pressure.

A focus on higher acuity devices, S11 price premium, surcharges and lesser rebates/discounts may somewhat alleviate the higher costs, the broker suggests, but then rising rates are also a headwind.

Target falls to $26.90 from $33.10, Equal-weight retained.

FORECAST
Morgan Stanley forecasts a full year FY22 dividend of 22.92 cents and EPS of 79.96 cents.
Morgan Stanley forecasts a full year FY23 dividend of 22.92 cents and EPS of 89.92 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

RMD STOCK CHART